Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs

Sayer I. Al-Azzam, Lawrence Fleckenstein, Kuei Ju Cheng, Michael T. Dzimianski, John W. McCall

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

This study compares plasma disposition kinetics of ivermectin and moxidectin after oral administration to beagle dogs experimentally infected with the filarial parasite, Brugia pahangi. Sixteen dogs were selected and randomly allocated into two groups of eight dogs each. Animals in each group received either ivermectin or moxidectin by oral route at a dose of 250 μg/kg. Blood samples were collected from 0.5h up to 56 days post-treatment and the plasma was analysed by high performance liquid chromatography (HPLC). The obtained data were analysed by compartmental and non-compartmental pharmacokinetic techniques. Peak plasma concentrations (Cmax) of 234.0 ± 64.3 ng/ml (mean ± SD) were obtained for moxidectin and 132.6 ± 43.0 ng/ml for ivermectin. The terminal elimination half-life was significantly (p ss/F was obtained for moxidectin (19.21 ± 3.611/kg) compared with ivermectin (5.35 ± 1.291/kg). The mean estimates of CL/F of moxidectin and ivermectin were 0.0220 ± 0.00381 and 0.0498±0.01791/h/kg, respectively. The comparative plasma disposition kinetics of ivermectin and moxidectin in dogs is reported for the first time.

Original languageEnglish
Pages (from-to)431-438
Number of pages8
JournalBiopharmaceutics and Drug Disposition
Volume28
Issue number8
DOIs
Publication statusPublished - Nov 2007
Externally publishedYes

Fingerprint

Ivermectin
Oral Administration
Pharmacokinetics
Dogs
Brugia pahangi
Half-Life
milbemycin
Parasites
High Pressure Liquid Chromatography

Keywords

  • Ivermectin
  • Moxidectin
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. / Al-Azzam, Sayer I.; Fleckenstein, Lawrence; Cheng, Kuei Ju; Dzimianski, Michael T.; McCall, John W.

In: Biopharmaceutics and Drug Disposition, Vol. 28, No. 8, 11.2007, p. 431-438.

Research output: Contribution to journalArticle

Al-Azzam, Sayer I. ; Fleckenstein, Lawrence ; Cheng, Kuei Ju ; Dzimianski, Michael T. ; McCall, John W. / Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. In: Biopharmaceutics and Drug Disposition. 2007 ; Vol. 28, No. 8. pp. 431-438.
@article{9debc92244994b28af18dcc98cc47dd5,
title = "Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs",
abstract = "This study compares plasma disposition kinetics of ivermectin and moxidectin after oral administration to beagle dogs experimentally infected with the filarial parasite, Brugia pahangi. Sixteen dogs were selected and randomly allocated into two groups of eight dogs each. Animals in each group received either ivermectin or moxidectin by oral route at a dose of 250 μg/kg. Blood samples were collected from 0.5h up to 56 days post-treatment and the plasma was analysed by high performance liquid chromatography (HPLC). The obtained data were analysed by compartmental and non-compartmental pharmacokinetic techniques. Peak plasma concentrations (Cmax) of 234.0 ± 64.3 ng/ml (mean ± SD) were obtained for moxidectin and 132.6 ± 43.0 ng/ml for ivermectin. The terminal elimination half-life was significantly (p ss/F was obtained for moxidectin (19.21 ± 3.611/kg) compared with ivermectin (5.35 ± 1.291/kg). The mean estimates of CL/F of moxidectin and ivermectin were 0.0220 ± 0.00381 and 0.0498±0.01791/h/kg, respectively. The comparative plasma disposition kinetics of ivermectin and moxidectin in dogs is reported for the first time.",
keywords = "Ivermectin, Moxidectin, Pharmacokinetics, Ivermectin, Moxidectin, Pharmacokinetics",
author = "Al-Azzam, {Sayer I.} and Lawrence Fleckenstein and Cheng, {Kuei Ju} and Dzimianski, {Michael T.} and McCall, {John W.}",
year = "2007",
month = "11",
doi = "10.1002/bdd.572",
language = "English",
volume = "28",
pages = "431--438",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs

AU - Al-Azzam, Sayer I.

AU - Fleckenstein, Lawrence

AU - Cheng, Kuei Ju

AU - Dzimianski, Michael T.

AU - McCall, John W.

PY - 2007/11

Y1 - 2007/11

N2 - This study compares plasma disposition kinetics of ivermectin and moxidectin after oral administration to beagle dogs experimentally infected with the filarial parasite, Brugia pahangi. Sixteen dogs were selected and randomly allocated into two groups of eight dogs each. Animals in each group received either ivermectin or moxidectin by oral route at a dose of 250 μg/kg. Blood samples were collected from 0.5h up to 56 days post-treatment and the plasma was analysed by high performance liquid chromatography (HPLC). The obtained data were analysed by compartmental and non-compartmental pharmacokinetic techniques. Peak plasma concentrations (Cmax) of 234.0 ± 64.3 ng/ml (mean ± SD) were obtained for moxidectin and 132.6 ± 43.0 ng/ml for ivermectin. The terminal elimination half-life was significantly (p ss/F was obtained for moxidectin (19.21 ± 3.611/kg) compared with ivermectin (5.35 ± 1.291/kg). The mean estimates of CL/F of moxidectin and ivermectin were 0.0220 ± 0.00381 and 0.0498±0.01791/h/kg, respectively. The comparative plasma disposition kinetics of ivermectin and moxidectin in dogs is reported for the first time.

AB - This study compares plasma disposition kinetics of ivermectin and moxidectin after oral administration to beagle dogs experimentally infected with the filarial parasite, Brugia pahangi. Sixteen dogs were selected and randomly allocated into two groups of eight dogs each. Animals in each group received either ivermectin or moxidectin by oral route at a dose of 250 μg/kg. Blood samples were collected from 0.5h up to 56 days post-treatment and the plasma was analysed by high performance liquid chromatography (HPLC). The obtained data were analysed by compartmental and non-compartmental pharmacokinetic techniques. Peak plasma concentrations (Cmax) of 234.0 ± 64.3 ng/ml (mean ± SD) were obtained for moxidectin and 132.6 ± 43.0 ng/ml for ivermectin. The terminal elimination half-life was significantly (p ss/F was obtained for moxidectin (19.21 ± 3.611/kg) compared with ivermectin (5.35 ± 1.291/kg). The mean estimates of CL/F of moxidectin and ivermectin were 0.0220 ± 0.00381 and 0.0498±0.01791/h/kg, respectively. The comparative plasma disposition kinetics of ivermectin and moxidectin in dogs is reported for the first time.

KW - Ivermectin

KW - Moxidectin

KW - Pharmacokinetics

KW - Ivermectin

KW - Moxidectin

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=36448990126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448990126&partnerID=8YFLogxK

U2 - 10.1002/bdd.572

DO - 10.1002/bdd.572

M3 - Article

VL - 28

SP - 431

EP - 438

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 8

ER -